|
| Press Releases |
|
 |
|
| Wednesday, September 28, 2016 |
|
|
Eisai Submits Supplemental Application for Partial Label Change for Antiepileptic Drug Fycompa |
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has submitted a supplemental application for its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel) proposing the inclusion in labelling of a description of use as monotherapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older to the U.S Food and Drug Administration (FDA) based on new FDA policy.
more info >> |
|
| Thursday, September 15, 2016 |
|
|
Eisai Receives License for New Indication for Anticancer Agent Kisplyx (Lenvatinib Mesylate) for Treatment of Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced that its European regional headquarters Eisai Europe Ltd. has received license from the European Commission for anticancer agent Kisplyx in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy. more info >> |
|
| Friday, August 26, 2016 |
|
|
Anticancer Agent "Treakisym for Injection 100 mg" Approved in Japan for Additional Indication of Chronic Lymphocytic Leukemia |
| Eisai Co., Ltd. announced today that the anticancer agent TREAKISYM for Injection 100 mg (generic name: bendamustine hydrochloride, "TREAKISYM") has been approved in Japan for an additional indication of chronic lymphocytic leukemia. more info >> |
|
| Tuesday, August 23, 2016 |
|
|
Eisai to Launch Chocola BB Mouth Ulcer Repair Shot |
| Eisai Co., Ltd. announced today that it will launch "Chocola BB Mouth Ulcer Repair Shot"(Third-class OTC drug) for mouth ulcers in Japan on Thursday, August 25. more info >> |
|
| Monday, August 1, 2016 |
|
|
Eisai Presents Results of Additional Analysis of Phase III Study of Anticancer Agent Halaven at 14th JSMO Annual Meeting Plenary Session |
| Eisai Co., Ltd. announced today that the results of an additional analysis of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven in patients with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). more info >> |
|
|
Eisai and Mamorio to Jointly Develop "Me-MAMORIO" Tracking Tool to Support People With Dementia Going Out |
| Eisai Co., Ltd. and MAMORIO, Inc. announced today that they have entered into an agreement to collaborate on the development of the MeMAMORIO1 tracking tool to support people with dementia going out. more info >> |
|
| Friday, July 22, 2016 |
|
|
Eisai Receives Positive CHMP Opinion on New Indication for Anticancer Agent Lenvatinib in Combination with Everolimus for Treatment of Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent lenvatinib mesylate in combination with everolimus. more info >> |
|
| Wednesday, July 20, 2016 |
|
|
U.S. FDA Approves BELVIQ XR, A Once-Daily Formulation of Lorcaserin for Chronic Weight Management |
| Eisai Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for BELVIQ XR, a once-daily formulation of lorcaserin hydrochloride (generic name, U.S. brand name: BELVIQ) for chronic weight management. more info >> |
|
| Thursday, June 30, 2016 |
|
|
Eisai listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 15th consecutive year since its initial inclusion in 2002. more info >> |
|
| Monday, June 20, 2016 |
|
|
AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease |
| AbbVie GK, Eisai Co., Ltd., and its subsidiary EA Pharma Co., Ltd. today announced the additional approval for a new dosing regimen of Humira Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection, a fully human anti-TNF monoclonal antibody formulation, in patients with moderate or severe Crohn's disease who become less responsive to treatment with 40 mg every two weeks to double the dose to 80 mg every two weeks. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Four HK designer labels shine at London Fashion Week
Feb 22, 2025 22:56 HKT/SGT
|
|
|
Dollamur Announces United World Wrestling Approval Through 2028
Feb 22, 2025 22:54 HKT/SGT
|
|
|
Yashaa Global Capital Secures Financial Services Permission to Establish a Global Sports VC Fund
Feb 22, 2025 20:11 HKT/SGT
|
|
|
AsiaMedic and Sunway launch new Medical Diagnostic Imaging Centre in Novena 
Feb 22, 2025 18:00 HKT/SGT
|
|
|
Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026
Feb 22, 2025 4:50 JST
|
|
|
Alexis Mc Allister Announces as Jeton's Latest Brand Ambassador
Feb 21, 2025 23:00 HKT/SGT
|
|
|
NaaS Technology Launches $10 Million Share Repurchase Plan Boosting Market Confidence
Feb 21, 2025 21:09 HKT/SGT
|
|
|
Honda Receives Highest Ranking of 3 Stars as Part of FIA Road Safety Index, Tool for Organizations and Companies to Measure Their Road Safety Footprint
Feb 21, 2025 19:40 JST
|
|
|
Carl Zeiss Honors EuroEyes International for Exceptional Milestone in AT LISA(R) Trifocal Lens Implantations
Feb 21, 2025 18:29 HKT/SGT
|
|
|
Honda Partners with United Nations Road Safety Fund (UNRSF) to Work Toward Reduction of Fatalities from Traffic Collisions
Feb 21, 2025 19:11 JST
|
|
|
Mitsubishi Logistics Corporation, Mitsubishi Corporation, and Yourstand Inc. Advancing Completely CO2-Free Electrification of Pharmaceutical Transportation
Feb 21, 2025 15:01 JST
|
|
|
NEC Innovation Challenge awards Canada's Prevu3D Inc. with the NEC Award and NOFF Award
Feb 21, 2025 14:39 JST
|
|
|
NEC Develops Near Real-time RIC for High Performance 5G vRAN
Feb 21, 2025 12:00 JST
|
|
|
Igloo kicks off 2025 with Multi-market Partnership Wins and Chief Distribution Officer Appointment
Feb 21, 2025 09:00 HKT/SGT
|
|
|
Giftify, Inc. Announces Smart Savings Solution for Popular GLP-1 Diabetes and Weight Loss Medications
Feb 21, 2025 08:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
